TCF7 and adenocarcinoma: Two studies proposed that better effectors were derived from CD8+ PD-1+ TCF7+stem-like T cells, based on observations that PD1-IL2v expands CD8+ PD-1+ TCF7+ T cells in Panc02-H7-Fluc adenocarcinoma [8], in spontaneous pancreatic tumors of RIP1-Tag5 mice [9], and in mouse GL261 gliomas [9], validating this T cell subset as the putative target of this therapy.